Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 12, 2015, Pages H1564-H1574

  Teng, Guoqi ^a   Svystonyuk, Daniyil ^a   Mewhort, Holly E M ^a   Turnbull, Jeannine D ^a   Belke, Darrell D ^a   Duff, Henry J ^a   Fedak, Paul W M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Diastolic Dysfunction; Extracellular Matrix; Fibroblast; Fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; FIBRONECTIN; MESSENGER RNA; TETRANDRINE; TROPONIN I; VIMENTIN; VON WILLEBRAND FACTOR; ACTA2 PROTEIN, HUMAN; ACTIN; BENZYLISOQUINOLINE DERIVATIVE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHELATING AGENT; GEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CELL ACTIVATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FLOW CYTOMETRY; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CARDIOMYOPATHIES; CELL CULTURE; DAHL RAT; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; GEL; GENETICS; HEART ATRIUM APPENDAGE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HYPERTENSION; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

ACTINS; ANIMALS; ATRIAL APPENDAGE; BENZYLISOQUINOLINES; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHELATING AGENTS; CARDIOMYOPATHIES; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; GELS; HUMANS; HYPERTENSION; MALE; MYOFIBROBLASTS; RATS, INBRED DAHL; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84931043115     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00126.2015     Document Type: Article

References (41)

1. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP, Janicki JS. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 30: 604–610, 2006.
2. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45: 657–687, 2005.
3. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 117: 1630–1641, 2008.
4. Chen H, Chen SC, Zhang TH, Tian HC, Guan Y, Su DF. Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion. Int J Cardiol 41: 103–108, 1993.
5. Dawson K, Wu CT, Qi XY, Nattel S. Congestive heart failure effects on atrial fibroblast phenotype: differences between freshly-isolated and cultured cells. PLos One 7: e52032, 2012.
6. Fedak PWM, Verma S, Weisel RD, Li RK. Cardiac remodeling and failure. From molecules to man (part II). Cardiovasc Pathol 14: 49–60, 2005.
7. Goldsmith EC, Bradshaw AD, Spinale FG. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol 304: C393–C402, 2013.
8. Grinnell F. Fibroblast-collagen-matrix contraction: growth-factor signalling and mechanical loading. Trends Cell Biol 10: 362–365, 2000.
9. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 170: 1807–1816, 2007.
10. Huang YT, Cheng YR, Lin HC, Chen CF, Hong CY. Hemodynamic effects of chronic tetrandrine treatment in Sprague-Dawley rats. Chin J Physiol 40: 175-178, 1997.
11. Kang J. [Effects of tetrandrine on pulmonary hypertension in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi 16: 93-94, 124, 1993.
12. Kitano A, Yamanaka O, Ikeda K, Ishida-Nishikawa I, Okada Y, Shirai K, Saika S. Tetrandrine suppresses activation of human subconjunctival fibroblasts in vitro. Curr Eye Res 33: 559-565, 2008.
13. Kwan CY, Achike FI. Tetrandrine and related bis-benzylisoquinoline alkaloids from medicinal herbs: cardiovascular effects and mechanisms of action. Acta Pharmacol Sin 23: 1057-1068, 2002.
14. Lijnen P, Petrov V, Rumilla K, Fagard R. Transforming growth factor-beta 1 promotes contraction of collagen gel by cardiac fibroblasts through their differentiation into myofibroblasts. Methods Find Exp Clin Pharmacol 25: 79-86, 2003.
15. Liu W, Zhang J, Ying C, Wang Q, Yan C, Jingyue Y, Zhaocai Y, Yan X, Heng-Jun S, Lin J. Tetrandrine combined with gemcitabine and Cisplatin for patients with advanced non-small cell lung cancer improve efficacy. Int J Biomed Sci 8: 28-35, 2012.
16. Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Intern Med 158: 2225-2234, 1998.
17. Masur SK, Dewal HS, Dinh TT, Erenburg I, Petridou S. Myofibroblasts differentiate from fibroblasts when plated at low density. Proc Natl Acad Sci U S A 93: 4219–4223, 1996.
18. Mewhort HE, Turnbull JD, Meijndert HC, Ngu JM, Fedak PW. Epicardial infarct repair with basic fibroblast growth factor-enhanced CorMatrix-ECM biomaterial attenuates postischemic cardiac remodeling. J Thorac Cardiovasc Surg 147: 1650-1659, 2014.
19. Mohammadi H, Janmey PA, McCulloch CA. Lateral boundary mecha-nosensing by adherent cells in a collagen gel system. Biomaterials 35: 1138-1149, 2014.
20. Ngu JM, Teng G, Meijndert HC, Mewhort HE, Turnbull JD, Stetler-Stevenson WG, Fedak PW. Human cardiac fibroblast extracellular matrix remodeling: dual effects of tissue inhibitor of metalloproteinase-2. Cardiovasc Pathol 23: 335-343, 2014.
21. Nobre F, Mion D. Is the area under blood pressure curve the best parameter to evaluate 24-h ambulatory blood pressure monitoring data? Blood Press Monit 10: 263-270, 2005.
22. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355: 251-259, 2006.
23. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Édes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28: 2539-2550, 2007.
24. Pinelli A, Trivulzio S, Brenna S, Galmozzi G, Rossoni G. Pretreatment with tetrandrine has protective effects against isoproterenol-induced myocardial infarction in rabbits. In Vivo 24: 265-270, 2010.
25. Rao MR. Effects of tetrandrine on cardiac and vascular remodeling. Acta Pharmacol Sin 23: 1075-1085, 2002.
26. Rose RA, Belke DD, Maleckar MM, Giles WR. Ca2+ entry through TRP-C channels regulates fibroblast biology in chronic atrial fibrillation. Circulation 126: 2039-2041, 2012.
27. Santiago JJ, Dangerfield AL, Rattan SG, Bathe KL, Cunnington RH, Raizman JE, Bedosky KM, Freed DH, Kardami E, Dixon IM. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 239: 1573-1584, 2010.
28. Shen DF, Tang QZ, Yan L, Zhang Y, Zhu LH, Wang L, Liu C, Bian ZY, Li H. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling. Br J Pharmacol 159: 970-981, 2010.
29. Shen YC, Chen CF, Sung YJ. Tetrandrine ameliorates ischaemia-reper-fusion injury of rat myocardium through inhibition of neutrophil priming and activation. Br J Pharmacol 128: 1593-1601, 1999.
30. Soldatov NM. Molecular diversity of L-type Ca2+ channel transcripts in human fibroblasts. Proc Natl Acad Sci USA 89: 4628-4632, 1992.
31. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 7: 30-37, 2010.
32. Wang G, Lemos JR. Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca+-activated K+ channels. Life Sci 56: 295-306, 1995.
33. Wang J, Chen H, Seth A, McCulloch CA. Mechanical force regulation of myofibroblast differentiation in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 285: H1871-H1881, 2003.
34. Weber K, Sun Y, Tyagi S, Cleutjens J. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 26: 279-292, 1994.
35. Wong TM, Wu S, Yu XC, Li HY. Cardiovascular actions of Radix Stephaniae Tetrandrae: a comparison with its main component, tetrandrine. Acta Pharmacol Sin 21: 1083-1088, 2000.
36. Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang GJ. Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats. Tumori 96: 460-464, 2010.
37. Xu Y, Rao MR. Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Eur J Pharmacol 278: 1–7, 1995.
38. Yeh YH, Kuo CT, Chang GJ, Qi XY, Nattel S, Chen WJ. Nicotin-amide adenine dinucleotide phosphate oxidase 4 mediates the differential responsiveness of atrial versus ventricular fibroblasts to transforming growth factor-beta. Circ Arrhythm Electrophysiol 6: 790–798, 2013.
39. Yu XC, Wu S, Chen CF, Pang KT, Wong TM. Antihypertensive and anti-arrhythmic effects of an extract of Radix Stephaniae Tetrandrae in the rat. J Pharm Pharmacol 56: 115–122, 2004.
40. Yue L, Xie J, Nattel S. Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation. Car-diovasc Res 89: 744–753, 2011.
41. Zunwen L, Shizhen Z, Dewu L, Yungui M, Pu N. Effect of tetrandrine on the TGF-beta-induced smad signal transduction pathway in human hypertrophic scar fibroblasts in vitro. Burns 38: 404–413, 2012.